Alterity Therapeutics (ASX:ATH) EV-to-EBITDA: (As of Jul. 31, 2026)

Alterity Therapeutics  (ASX:ATH) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Alterity Therapeutics's PE Ratio (TTM) for today is calculated as:

Alterity Therapeutics's share price for today is A$0.545.
Alterity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Alterity Therapeutics EV-to-EBITDA Related Terms

The historical data trend for Alterity Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics EV-to-EBITDA Chart

Alterity Therapeutics Annual Data
	Trend	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24	Jun25	Jun26
EV-to-EBITDA		Get a 7-Day Free Trial					0.23	-0.11	-0.44	-4.16	0.00

Alterity Therapeutics Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26	Jun26
EV-to-EBITDA	Get a 7-Day Free Trial															-4.16	0.00	0.00	0.00	0.00

ASX:ATH vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison

For the Biotechnology subindustry, Alterity Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's EV-to-EBITDA falls into.

Alterity Therapeutics EV-to-EBITDA Calculation

Alterity Therapeutics's EV-to-EBITDA for today is calculated as:

Alterity Therapeutics's current Enterprise Value is A$69.44 Mil.
Alterity Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Business Description